This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisFDA EventsInsider TradesTrendsBuy This Stock About Alimera Sciences Stock (NASDAQ:ALIM) Get Alimera Sciences alerts:Sign Up Key Stats Today's Range$5.54▼$5.5450-Day Range$5.19▼$5.6052-Week Range$2.61▼$5.65VolumeN/AAverage Volume376,318 shsMarket Capitalization$290.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Read More Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALIM Stock News HeadlinesANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside PotentialMarch 21, 2026 | finance.yahoo.comANI Pharmaceuticals Reshapes Portfolio With Alimera Deal And Rare Disease PushMarch 2, 2026 | finance.yahoo.comMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson says what's unfolding in New York City is just the beginning. Tilson, a Harvard MBA who spent 30 years on Wall Street, has identified a specific economic pattern he believes points to a financial reset unlike anything seen in over 100 years. He's released a free analysis outlining what's coming and the exact steps he recommends you take with your money now.June 24 at 1:00 AM | Stansberry Research (Ad)Alimera Sciences Inc.March 19, 2025 | money.usnews.comANI Pharmaceuticals’ Record Growth and Strategic AcquisitionNovember 9, 2024 | markets.businessinsider.comANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target PriceSeptember 18, 2024 | markets.businessinsider.comAlimera Sciences, Inc. (NASDAQ:ALIM): When Will It Breakeven?September 12, 2024 | finance.yahoo.comAlimera Sciences, Inc. (ALIM)September 11, 2024 | finance.yahoo.comSee More Headlines ALIM Stock Analysis - Frequently Asked Questions How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) issued its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company earned $27 million during the quarter, compared to the consensus estimate of $25.76 million. Alimera Sciences had a negative trailing twelve-month return on equity of 33.70% and a negative net margin of 14.74%. When did Alimera Sciences' stock split? Alimera Sciences shares reverse split before market open on Friday, November 15th 2019.The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Alimera Sciences IPO? Alimera Sciences (ALIM) raised $0 in an IPO on Thursday, April 22nd 2010. The company issued 0 shares at $15.00-$17.00 per share. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alimera Sciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/06/2024Today6/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALIM CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees150Year Founded2003Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.13 million Net Margins-14.74% Pretax Margin-14.76% Return on Equity-33.70% Return on Assets-9.63% Debt Debt-to-Equity Ratio1.80 Current Ratio2.79 Quick Ratio2.62 Sales & Book Value Annual Sales$99.68 million Price / Sales2.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book6.30Miscellaneous Outstanding Shares52,389,000Free Float35,939,000Market Cap$290.24 million OptionableNo Data Beta1.25 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ALIM) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredBig Oil knew about this for 50 yearsIn the 1970s, Chevron, Unocal, and Texaco all drilled the same energy source - and walked away to protect oil ...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredMy #1 Way to Gain Exposure to Anthropic Before It IPOsAnthropic just filed with the SEC to go public at a $965 billion valuation - and Wall Street veteran Marc Chai...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alimera Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
